Evidence map›Paper›PMID 37028468›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2023

Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon.

Peter Thelma Ngwa Niba, Akindeh Mbuh Nji, Jean Paul Kengne Chedjou, Helle Hansson, Emma Filtenborg Hocke, Innocent Mbulli Ali, Olivia Achonduh-Atijegbe, Marie-Solange B Evehe, Marie Helene Munck Jørgensen, Calvino Tah Fomboh and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. NovelAntimicrobial agents and chemotherapy · 2025
    Article
  5. Article
  6. Article
  7. Application of a new highly multiplexed amplicon sequencing tool to evaluatemedRxiv : the preprint server for health sciences · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Peter Thelma Ngwa NibaMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon; Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon.
Akindeh Mbuh NjiMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon; Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon.
Jean Paul Kengne ChedjouMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon; Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, Buea, Cameroon.
Helle HanssonCenter for Medical Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Emma Filtenborg HockeCenter for Medical Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Innocent Mbulli AliMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon; Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon.
Olivia Achonduh-AtijegbeMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
Marie-Solange B EveheMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
Marie Helene Munck JørgensenCenter for Medical Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Calvino Tah FombohMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon; Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon.
Liwang CuiCenter for Global Health and Infectious Disease Research, University of South Florida, Tampa, United States of America.
Gillian StresmanEpidemiology Concentration, College of Public Health, University of South Florida, Tampa, United States of America; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Jude D BigogaMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon; Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon.
Michael AlifrangisCenter for Medical Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Wilfred F MbachamMARCAD-DELTAS Program, Laboratory for Public Health Research Biotechnologies, University of Yaounde I, Yaounde, Cameroon; The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon; Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon; Fobang Institutes for Innovations in Science and Technology, Yaounde, Cameroon; Faculty of Natural and Agricultural Sciences, North-West University, Mmabatho, South Africa. Electronic address: wfmbacham@yahoo.com.

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
Northern/Pacific Universities Global Health Research Training ConsortiumR25TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI KOLARS, JOSEPH C., NERURKAR, VIVEK RAMCHANDRA · 2012 to 2016
$5.9M
Training of Cameroonian Scientists in Research on MalariaD43TW009074 · FIC · UNIVERSITY OF HAWAII AT MANOA · PI NERURKAR, VIVEK RAMCHANDRA · 2011 to 2015
$978k
FIC NIH HHS D43 TW009074FIC NIH HHS R25 TW009345NIAID NIH HHS U19 AI089672Wellcome Trust
6 · The paper itself

Abstract

objectivesThis study aimed to investigate the evolution of Plasmodium falciparum antimalarial drug resistance markers by comparing the pre- and post-adoption of artemisinin-based combination therapies (ACTs) in Yaounde, Cameroon.

methodsThe molecular characterization of known antimalarial drug resistance markers (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, and Pfk13) in P. falciparum-positive samples collected in 2014 and 2019-2020 was achieved using nested polymerase chain reaction, followed by targeted amplicon deep sequencing on the Illumina MiSeq platform. Data derived were compared with those published during the pre-ACT adoption period from 2004 to 2006.

resultsA high prevalence of Pfmdr1 184F, Pfdhfr 51I/59R/108N, and Pfdhps 437G mutant alleles was observed during the post-ACT adoption period. The Pfcrt 76T and Pfmdr1 86Y mutant alleles significantly declined between 2004 and 2020 (P <0.0001). Conversely, the resistance markers to antifolates, Pfdhfr 51I/59R/108N and Pfdhps 437G, significantly increased during the same study period (P <0.0001). We identified nine mutations in the propeller domains of Pfk13; although they were all present in single parasite isolates, none of them are known to confer artemisinin resistance.

conclusionThis study documented a near-complete reversion to sensitive parasites for markers conferring resistance to the 4-aminoquinolines and arylamino alcohols in Yaounde. In contrast, the Pfdhfr mutations associated with pyrimethamine resistance are moving toward saturation.

Indexed as

AntimalarialsArtemisininsMalaria, FalciparumCameroonDrug CombinationsHumansPlasmodium falciparumProtozoan ProteinsSulfadoxineAntimalarialsartemisininArtemisininsDrug CombinationsProtozoan ProteinsSulfadoxineArtemisinin-based combination therapiesCameroonDrug resistanceEvolutionPlasmodium falciparumTargeted amplicon deep sequencing

Identifiers

PMID37028468
PMCPMC10182900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.